Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer

Leung, E. Y.L. , Scott, H. R. and McMillan, D. C. (2012) Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. Journal of Thoracic Oncology, 7(4), pp. 655-662. (doi:10.1097/JTO.0b013e318244ffe1) (PMID:22425914)

Full text not currently available from Enlighten.


Introduction: Traditional tumor-based staging systems provide limited information on the best treatment option for individual patients with advanced inoperable non-small cell lung cancer (NSCLC). The Glasgow prognostic score (GPS) reflects the host systemic inflammatory response and is a validated independent prognostic factor in these patients. The aim of this study was to examine the clinical application of the pretreatment GPS in a mature cohort of patients with inoperable NSCLC. Methods: The data of 261 patients with inoperable NSCLC were collected prospectively and before treatment. Information on patient demographics, body mass index, performance status (PS), the modified Glasgow prognostic score (mGPS), the prognostic index, and treatment received were included. Results: The majority of patients were aged 65 years or older (68%), were men (59%), had a body mass index more than 20 (89%), and an Eastern Cooperative Oncology Group performance status (ECOG-PS) 0 or 1 (54%). Most patients had a pretreatment mGPS = 1 (62%) and pretreatment prognostic index = 1 (56%). During the follow-up period, 248 (95%) patients died, 246 from their disease. The median survival was 8 months. On multivariate analysis, age (p = 0.001), ECOG-PS (p < 0.05), mGPS (p < 0.0001), and tumor stage (p < 0.0001) were independently associated with cancer-specific survival. Using 5-year cancer-specific mortality as an end point, the area under the receiver operator curve was 0.735 (95% confidence interval [CI], 0.566–0.903; p = 0.024) for the mGPS, 0.669 (95% CI, 0.489–0.848; p = 0.106) for ECOG-PS, and 0.622 (95% CI, 0.437–0.807; p = 0.240) for tumor, node, metastasis stage. Patients with an increased mGPS were more likely to have a poorer ECOG-PS (p < 0.05), an increased white cell count (p < 0.05), and received palliative treatment (p < 0.05). Conclusion: The pretreatment mGPS is a useful and important predictor of cancer-specific survival in patients with inoperable NSCLC. Basing clinical assessment on the mGPS has implications for the routine monitoring and treatment of the patients.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Scott, Professor Hazel and McMillan, Professor Donald and Leung, Dr Elaine
Authors: Leung, E. Y.L., Scott, H. R., and McMillan, D. C.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Journal of Thoracic Oncology
ISSN (Online):1556-1380

University Staff: Request a correction | Enlighten Editors: Update this record